# Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

> **NCT00847899** · PHASE2 · COMPLETED · sponsor: **Arete Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Hypertension
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** AR9281
- **DRUG:** AR9281
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00847899
- **Lead sponsor:** Arete Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847899, "Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00847899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*